Navigation Links
NUCRYST appoints interim CEO
Date:1/19/2009

PRINCETON, NJ, Jan. 19 /PRNewswire-FirstCall/ - The Board of Directors of NUCRYST Pharmaceuticals Corp. today announced the appointment of David B. Holtz as interim President and Chief Executive Officer of the Company and Neil Carragher as Chairman, effective immediately. Mr. Holtz replaces Thomas E. Gardner, who was Chairman, President and Chief Executive Officer. Mr. Carragher, currently lead director of NUCRYST, will assume the role of Chairman, effective immediately. Mr. Holtz will also remain as CFO.

Previously, Mr. Holtz was Vice President and Chief Financial Officer of NUCRYST.

"David's experience and skills will be beneficial to NUCRYST as management focuses all efforts on bringing the company to profitability," said Mr. Carragher. "We thank Tom Gardner for his many contributions to the company and for his dedicated service."

Before joining NUCRYST, Mr. Holtz served as a financial management consultant for various start-up companies, including Virium Pharmaceuticals, Inc. Previously he worked in managerial roles of increasing importance at Integra LifeSciences Holdings Corporation from October 1993 through December 2006, most recently as Senior Vice President Finance. While at Integra, Mr. Holtz oversaw Integra's European operations to support the transition of acquisitions in Europe and managed all worldwide financial reporting and accounting functions. Prior to Integra, he worked for Coopers & Lybrand LLP and Cono Leasing Corporation. Mr. Holtz received a B.S. in Business Administration with an emphasis on finance from Susquehanna University.

NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM), its patented atomically disordered nanocrystalline silver technology. NUCRYST licensed wor
'/>"/>

SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. NUCRYST Pharmaceuticals appoints a new director
2. NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder
3. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
4. NUCRYST Receives Deficiency Notice from NASDAQ
5. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
6. NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer
7. NUCRYST Announces First Quarter 2008 Financial Results
8. NUCRYST Announces Management Realignment and R&D Portfolio Change
9. NUCRYST Announces Senior Management Change
10. NUCRYST Pharmaceuticals announces year-end results
11. NUCRYST Pharmaceuticals announces 2007 third quarter results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... first identified more than 15 years ago, the PTEN ... in preventing the onset and progression of numerous cancers. ... cells can grow unchecked and cancer can develop. , ... Deaconess Medical Center (BIDMC) helps explain more precisely how ... or alteration can set cells on a cancerous course. ...
(Date:4/24/2014)... Benefits often coexist with the negative and stressful outcomes ... later diagnosed with a life-limiting illness, says a recent ... Waterloo. , While the challenges are numerous and life-changing ... who participated in the Waterloo-led research reported positive outcomes ... findings appear in the most recent issue of the ...
(Date:4/24/2014)... Center for BrainHealth will bring together national experts ... challenges at its inaugural Brain Health Summit, titled ... speakers will include Dr. Sandra Bond Chapman, founder ... U.S. Senator Chuck Grassley (R-IA), U.S. Representative Chaka ... for Policy and Early Learning, U.S. Department of ...
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... 4/24/14) Dartmouth has been awarded one of 30 ... as a Lead Academic Participating Site in its new ... recipients are a select groups of investigators charged with ... cooperative groups., The NCTN grant system reflects recommendations from ... streamlines operations to achieve four goals:, Faster ...
Breaking Medicine News(10 mins):Health News:Surprising new insights into the PTEN tumor suppressor gene 2Health News:Surprising new insights into the PTEN tumor suppressor gene 3Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3
... The University of Texas M. D. Anderson Cancer Center ... significant role in determining// the aggressiveness of prostrate cancer. ... October 1 issue of Clinical Cancer Research, corroborates findings ... the development of prostate cancer. Sara Strom, Ph.D., an ...
... insulin therapy is the recommended method of diabetes management ... still want of an intravenous insulin protocol that is ... and simple enough to be used throughout the hospital ... Diabetes Associates, Georgia, led by Paul C. Davidson has ...
... Phase II study to 12 months confirm the significant effects ... patients with relapsing multiple sclerosis (MS). ,The data, ... both patient groups taking FTY720 (1.25 mg and 5 mg) ... of more than 50% during the first six months of ...
... In a path-breaking surgery here, an elderly woman suffering ... was relieved of the diseased parts without any trauma ... led by B. Ramana performed the two-hour-long operation - ... breast approach at Apollo Gleneagles Clinic last week. ...
... a chronic illness that requires continuing medical care ... and to reduce the risk of long-term complications//. ... primary care practitioners are confronted with an ever-increasing ... nephropathy. Undiagnosed chronic kidney disease (CKD) is common ...
... from Barts and London Queen Mary’s School of Medicine, ... microarray to find the gene which is probably responsible ... gene which on mutations leads to Basal cell carcinoma, ... in 60,000 patients each year, causing 500 deaths yearly. ...
Cached Medicine News:Health News:Novartis MS Drug Shows Promising Results 2Health News:Novartis MS Drug Shows Promising Results 3Health News:Endoscopic Thyroidectomy Helps In Removing Thyroid Cysts 2
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Health, offering best-in-class clinical, consulting and commercial services ... signed a definitive agreement to purchase PharmaNet Development ... services to the pharmaceutical, biotechnology, generic drug and ... were not disclosed. With the addition ...
... sustainable chemical company founded by Richard Gross , ... and biological sciences at Polytechnic Institute of New York ... Small Business Innovation Research (SBIR) grant from the ... for small, highly innovative technology businesses. ...
Cached Medicine Technology:inVentiv Health to Acquire PharmaNet 2inVentiv Health to Acquire PharmaNet 3inVentiv Health to Acquire PharmaNet 4inVentiv Health to Acquire PharmaNet 5SyntheZyme Wins Second National Science Foundation Grant to Commercialize Promising Biopesticide 2SyntheZyme Wins Second National Science Foundation Grant to Commercialize Promising Biopesticide 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... features including aspiration holes and additional ... procedures requiring precise dissection with decreased ... suction demands. ,Flexible design options ... nonretractable electrodes and multiple tip designs. ...
... including aspiration holes and additional electrode ... requiring precise dissection with decreased risk ... demands. ,Flexible design options allow ... electrodes and multiple tip designs. Optimize ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: